Novartis "buy"

25.09.06 - Jyske Bank

LONDON, September 25 (newratings.com) - Analysts at Jyske Bank maintain their "buy" rating on Novartis (NOVN). The target price is set to CHF85.

In a research note published this morning, the analysts mention that the company's product pipeline includes the launch of several new products going forward. The analysts expect Novartis to witness sustained robust development in its pharmaceutical business going forward, driven by the sales of its key products.